Mercodia CPEP3 Assay
C-peptide is a standard measure of pancreatic beta cell function and is used to assess the health of patients, especially those with diabetes. The CPEP3 test is highly specific, precise and offers a low Picomolar measuring range, an advantage not found with any other C-peptide assay on the market today. The ultrasensitive aspects of the CPEP3 Assay are important so as to provide a test that is highly quantitative and reliable with specificity and sensitivity that provides predictive results and minimal cross reactivity.
Various groups, including the AACC (American Association for Clinical Chemistry) and Dr. Denise Faustman, Massachusetts General, Boston MA, have highlighted the value of this assay in several peer-reviewed publications. The CPEP3 assay not only has important potential implications for patients and clinicians, it also allows for changes in inclusion criteria and monitoring during trials that assess treatments targeting those with long-term Type 1 diabetes. This can lead to interventional therapies to mitigate the life-threatening complications of diabetes.
SBH Diagnostics will include the CPEP3 in their CLIA Lab test portfolio, making it available to clinicians in addition to those conducting clinical trials and companies involved with diabetes diagnosis, management, therapeutics and devices.
Thank you for your interest in SBH Diagnostics literature and references.
1)Persistence of Prolonged C-peptide Production in Type 1 Diabetes as Measured With an Ultrasensitive C-peptide Assay. LIMEI WANG, PHD NICHOLAS FRASER LOVEJOY, BS DENISE L. FAUSTMAN, MD, PHD
2)Functional β cells detected in long-standing T1DM—a new hope for intervention? Joana Osório; Nature Reviews Endocrinology 8, 256 (2012); published online 13 March 2012; doi:10.1038/nrendo.2012.32